Recent litigation and actions by the FDA are exposing more women, and even young girls, to the impact of abortion pills on their mental and physical well-being. These steps are reshaping the landscape of abortion provision and posing new challenges in pursuing a culture of life and tracking the harms uniquely traceable to chemical abortion distribution with virtually no safeguards. We will discuss the evolution of the fight over abortion pills and describe how CLI pursued original research on the Medicaid population to determine the real impact of Mifeprex on the next generation of American women. Presented By: Genevieve Plaster; Tessa Longbons